PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug‐drug interactions (DDIs) and may offer an alternative to dedicated cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanke, Nina, Frechen, Sebastian, Moj, Daniel, Britz, Hannah, Eissing, Thomas, Wendl, Thomas, Lehr, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202474/
https://www.ncbi.nlm.nih.gov/pubmed/30091221
http://dx.doi.org/10.1002/psp4.12343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202474/
https://www.ncbi.nlm.nih.gov/pubmed/30091221
http://dx.doi.org/10.1002/psp4.12343

Ejemplares similares